Research programme: cell cycle inhibitors - Cyclacel/CV TherapeuticsAlternative Names: Cell cycle inhibitors research programme - Cyclacel/CV Therapeutics
Latest Information Update: 03 Mar 2006
At a glance
- Originator CV Therapeutics; Cyclacel
- Mechanism of Action Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Mar 2006 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 03 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 23 Jan 2001 Preclinical development for Cancer in United Kingdom (Unknown route)